Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals (AERI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aerie Pharmaceuticals 4301 Emperor Boulevard Suite 400 North Carolina NC 27703 USA

P: 919-237-5300

Description:

Aerie Pharmaceuticals is a commercial-stage company focused on the development and commercialization of eye disease therapies including glaucoma and other eye-diseases.'In 2017, Aerie received FDA approval for its lead drug, Rhopressa, for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa is a once-daily formulation for IOP in patients suffering from open-angle glaucoma and ocular hypertension. The FDA also approved Rocklatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Glaucoma is one of the largest segments in the global ophthalmic market.'In addition, the company is developing sustained-release implants focused on retinal indications. These include AR-13503 (Rho kinase and Protein kinase C inhibitor implant) for macular edema due to retinal vein occlusion(RVO) and AR-1105 (dexamethasone steroid implant) for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).'

Key Statistics

Overview:

Market Capitalization, $K 753,609
Enterprise Value, $K 613,809
Shares Outstanding, K 49,417
Annual Sales, $ 194,130 K
Annual Net Income, $ -74,810 K
Last Quarter Sales, $ 36,130 K
Last Quarter Net Income, $ -26,830 K
60-Month Beta -0.06
% of Insider Shareholders 4.44%
% of Institutional Shareholders 95.94%
Float, K 47,223
% Float 95.56%
Short Volume Ratio 0.64

Growth:

1-Year Return 48.49%
3-Year Return -18.14%
5-Year Return -75.12%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 71.47%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.27 on 11/03/22
Next Earnings Date N/A
Earnings Per Share ttm -0.16
EPS Growth vs. Prev Qtr 15.62%
EPS Growth vs. Prev Year 62.50%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

AERI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -2.00%
Profit Margin % -38.54
Net Margin % N/A
Debt/Equity N/A
Price/Sales 3.88
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -3.32
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar